<DOC>
	<DOCNO>NCT02711683</DOCNO>
	<brief_summary>Alzheimer 's disease ( AD ) common cause dementia . There effective treatment cure disease . Cholinesterase inhibitor , donepezil , widely recommend patient mild moderate AD . But cognitive function patient use donepezil gradually aggravate , Mini-Mental State Examination ( MMSE ) score fall 2 point per year average , donepezil effectively delay AD progress . DL-3-n-butylphthalide ( NBP ) synthetic chiral compound contain L- D-isomers butylphthalide . It develop L-3-n-butylphthalide , initially isolated pure component seed Apium graveolens 1978 researcher Institute Medicine Chinese Academy Medical Sciences . Studies past several decade demonstrate NBP effective alleviate oxidative damage mitochondrion dysfunction , improve microcirculation . NBP approve State Food Drug Administration China ( SFDA ) therapeutic drug treatment ischemic stroke 2005 Not ischemic stroke , NBP report increase expression N-methyl-D-aspartate subtype glutamate receptor 2B ( NR2B ) synaptophysin hippocampus age rat chronic cerebral hypoperfusion increase brain acetylcholine level , important process involve learning memory . It could alleviate learn memory deficit induce cerebral ischemia rat . A multicentre , randomize , double-blind , placebo-controlled trial conduct Professor Jia investigate NBP effective improve cognitive global functioning patient subcortical vascular cognitive impairment without dementia exhibit good safety 6-month treatment period . The pathogenesis AD involve mitochondrion dysfunction microcirculation dysfunction , action target NBP . Investigators observe MMSE score lower slowly use NBP treatment patient mild moderate AD already receive donepezil . But investigator lack system evaluation follow-up . Hence , investigator hypothesize NBP may therapeutic efficacy patient AD design present study .</brief_summary>
	<brief_title>DL-3-n-butylphthalide Treatment Patients With Mild Moderate Alzheimer 's Disease Already Receiving Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>3-n-butylphthalide</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>literate Chinese , age 5085 year , consistent caregiver accompany subject least 4 day week，2 hour day ; complaint and/or informant report cognitive impairment involve memory and/or cognitive domain last least 12 month ; progress gradually . diagnosis probable AD accord National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ; minimental state examination ( MMSE ) score ≥11 ≤22 ( primary school ) ≥11 ≤26 ( junior school ) ; Hachinski ischemia scale score ≤4 ; All patient meet clinical criterion underwent brain magnetic resonance imaging ( MRI ) scan include hippocampal assessment screening . The MRI entry criterion follow : number cerebral infarct ( ≥20 mm diameter ) less 2 , without infarct thalamus , hippocampal entorhinal cortex , medial temporal lobe atrophy visual rating scale ( MTA ) score 2 degree . absent neurological sign ; use donepezil 3 month remain relatively stable； sign inform consent . severe white matter lesion ( WML ) ( score ≥3 accord Fazekas rating scale ) , number cerebral infarct ( ≥20 mm diameter ) 2 , infarct important site , thalamus , hippocampal entorhinal cortex ; dementia due cause , vascular dementia , infection central nervous system，dementia Lewy body ( DLB ) ，etc suffer neurological disease , stroke , Parkinson 's disease , epilepsy； suffer mental disorder , schizophrenia，bipolar disorder，severe depression , delirium ; suffer unstable severe disorder heart , lung , liver , kidney blood system ; Severe impairment vision hearing ; Using cholinesterase inhibitor memantine .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>